Amgen Inc (AMGN) operating KPIs
AMGNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026Score 17/3039% above fair value
$466.01+5.28 (+1.15%)
Close on Oct 30, 2026Market cap $251.94BP/E 28.9Yield 2.07%
Amgen restructuring Charges (legacy standalone disclosure) ($M) ($M)
Form 10-K Restructuring Note (XBRL)
Latest, FY2023
267
Period ended Dec 31, 2023
Change on a year earlier
–
History
4 years
Since FY2015
Sources
2
Documents cited below
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Restructuring Charges (legacy standalone disclosure) ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2023 | Dec 31, 2023 | 267 | – | Form 10-K (filed 2024-02-14) ↗ |
| FY2017 | Dec 31, 2017 | 79 | +315.8% | Form 10-K (filed 2018-02-13) ↗ |
| FY2016 | Dec 31, 2016 | 19 | -85.6% | Form 10-K (filed 2018-02-13) ↗ |
| FY2015 | Dec 31, 2015 | 132 | – | Form 10-K (filed 2018-02-13) ↗ |
Breakdown
What makes up restructuring charges (legacy standalone disclosure) ($m)
Cite this data
StockData. (2026). Amgen Restructuring Charges (legacy standalone disclosure) ($M) ($M), annual FY2015–FY2023 [Data set]. Compiled from Amgen SEC filings and investor materials. https://stockdatahq.com/stocks/amgn/kpis/restruct_exp
See every metric in the Amgen KPI table. Data updated Oct 28, 2026.